TORONTO – Vancouver, British Columbia-based Izotropic Corp. has inked a deal with Victoria, British Columbia-based based Starfish Medical Inc. to commercialize a CT scanner Izotropic CEO Robert Thast said will be a major disruptor of the breast imaging industry. Izotropic has spent approximately $20 million over the past 15 years to develop the system and is counting on Starfish to help translate this into a market-ready 3D breast CT imager by the end of 2020.
BEIJING – Canbridge Pharmaceuticals Inc. is to add another source of income after Chinese regulators approved Nerlynx (neratinib) to be marketed for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer.
BEIJING – Beijing-headquartered Canbridge Pharmaceuticals Inc. is to add another source of income after Chinese regulators approved Nerlynx (neratinib) to be marketed for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.
With accelerated approval in hand for Trodelvy (sacituzumab govitecan-hziy) to treat metastatic triple-negative breast cancer (mTNBC), Immunomedics Inc. is looking ahead to data related to the next indication for the antibody-drug conjugate (ADC) – urothelial tumors – “in the near future,” Chairman Behzad Aghazadeh told investors during a conference call.
As expected – and well ahead of the Aug. 20 PDUFA date – Bothell, Wash-based Seattle Genetics Inc. (Seagen) won FDA clearance for the oral small-molecule breast cancer therapy tucatinib, a tyrosine kinase inhibitor branded Tukysa.
LONDON – A founding father of anti-angiogenesis therapy, Peter Carmeliet is turning his previous work on its head in new research which indicates that rather than destroying tumor vasculature, it should be piggy-backed as a means to recruit immune cells to a tumor.
Novi, Mich.-based startup Delphinus Medical Technologies Inc. has been working for roughly a decade to introduce whole breast ultrasound tomography to improve breast cancer diagnosis and treatment.
LONDON – Ibex Medical Analytics is preparing for commercial rollout in Europe after receiving CE-IVD marking for its artificial intelligence (AI) decision support system for automated interpretation of prostate cancer biopsies. Galen Prostate, trained on more than 60,000 samples from multiple institutions, is intended to give a second opinion on digitized slides, following initial assessment by a pathologist.
Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer.
Nantomics LLC, of Culver City, Calif., reported that research based on the company’s deep learning system has been published in a peer-reviewed journal, highlighting the algorithm’s ability to discern which mutation drives a patient’s breast cancer. The company said their approach is a rapid and cost-effective way to establish the breast cancer subtype, thus giving clinician and patient alike a good understanding of which therapies would be ineffective for that cancer and maximizing the chances for a cure.
